Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
TTR stabilizers work by binding to and stabilizing the TTR protein, preventing it from misfolding and forming amyloid fibrils. By stabilizing the TTR protein, these medications aim to slow down or halt the progression of the disease and potentially alleviate symptoms.
The global market for Transthyretin Stabilizer was estimated to be worth US$ 1480 million in 2023 and is forecast to a readjusted size of US$ 2372.8 million by 2030 with a CAGR of 6.9% during the forecast period 2024-2030
The global transthyretin stabilizer market refers to the market for medications and compounds used in the treatment of transthyretin amyloidosis (ATTR) by stabilizing the transthyretin (TTR) protein. This market encompasses various drugs that have been developed or under development as TTR stabilizers.
Currently, there are several TTR stabilizers that have gained regulatory approval or are in advanced stages of clinical development. The market is primarily driven by the rising prevalence of ATTR, increasing awareness of the disease, and the need for effective treatment options.
One of the key drugs in the market is tafamidis, which is approved in several countries for the treatment of ATTR polyneuropathy. Tafamidis has shown to stabilize TTR and slow disease progression in clinical trials. Other drugs such as diflunisal, AG10, inotersen, and patisiran are also being investigated and have shown promising results in clinical studies.
The market is expected to witness significant growth as more research is conducted on the development of TTR stabilizers and as regulatory approvals are obtained for these drugs in different regions. Additionally, the ongoing efforts to increase disease awareness among healthcare professionals and patients are likely to contribute to the market growth.
Key players in the global transthyretin stabilizer market include pharmaceutical companies such as Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, and Ionis Pharmaceuticals Inc., among others. These companies invest in research and development activities to develop new TTR stabilizers and expand their product portfolios.
Geographically, North America and Europe are leading regions in the market, primarily due to the higher prevalence of ATTR and the presence of established healthcare infrastructure. However, as awareness and diagnosis of ATTR improve in other regions such as Asia Pacific and Latin America, these regions are likely to exhibit significant growth opportunities.
In conclusion, the global transthyretin stabilizer market is expected to grow as more effective treatments are developed and approved for ATTR. The market is driven by the increasing prevalence of the disease and the need for therapies that can stabilize the TTR protein and slow disease progression.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Transthyretin Stabilizer, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Transthyretin Stabilizer by region & country, by Type, and by Application.
The Transthyretin Stabilizer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin Stabilizer.
麻豆原创 Segmentation
By Company
Pfizer Inc.
Merck & Co.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Corino Therapeutics Inc.
Alnylam Pharmaceuticals
Bellus Health Inc.
Ionis Pharmaceuticals, Inc.
Proclara Bioscience
Arturus Therapeutics
Prothena Corporation Plc.
Segment by Type:
Diflunisal
Tafamidis
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Transthyretin Stabilizer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Transthyretin Stabilizer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Transthyretin Stabilizer in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Transthyretin Stabilizer Product Introduction
1.2 Global Transthyretin Stabilizer 麻豆原创 Size Forecast
1.2.1 Global Transthyretin Stabilizer Sales Value (2019-2030)
1.2.2 Global Transthyretin Stabilizer Sales Volume (2019-2030)
1.2.3 Global Transthyretin Stabilizer Sales Price (2019-2030)
1.3 Transthyretin Stabilizer 麻豆原创 Trends & Drivers
1.3.1 Transthyretin Stabilizer Industry Trends
1.3.2 Transthyretin Stabilizer 麻豆原创 Drivers & Opportunity
1.3.3 Transthyretin Stabilizer 麻豆原创 Challenges
1.3.4 Transthyretin Stabilizer 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Transthyretin Stabilizer Players Revenue Ranking (2023)
2.2 Global Transthyretin Stabilizer Revenue by Company (2019-2024)
2.3 Global Transthyretin Stabilizer Players Sales Volume Ranking (2023)
2.4 Global Transthyretin Stabilizer Sales Volume by Company Players (2019-2024)
2.5 Global Transthyretin Stabilizer Average Price by Company (2019-2024)
2.6 Key Manufacturers Transthyretin Stabilizer Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Transthyretin Stabilizer Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Transthyretin Stabilizer
2.9 Transthyretin Stabilizer 麻豆原创 Competitive Analysis
2.9.1 Transthyretin Stabilizer 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Transthyretin Stabilizer Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Stabilizer as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Diflunisal
3.1.2 Tafamidis
3.1.3 Others
3.2 Global Transthyretin Stabilizer Sales Value by Type
3.2.1 Global Transthyretin Stabilizer Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Transthyretin Stabilizer Sales Value, by Type (2019-2030)
3.2.3 Global Transthyretin Stabilizer Sales Value, by Type (%) (2019-2030)
3.3 Global Transthyretin Stabilizer Sales Volume by Type
3.3.1 Global Transthyretin Stabilizer Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Transthyretin Stabilizer Sales Volume, by Type (2019-2030)
3.3.3 Global Transthyretin Stabilizer Sales Volume, by Type (%) (2019-2030)
3.4 Global Transthyretin Stabilizer Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Drug Stores
4.1.4 Online Pharmacies
4.1.5 Others
4.2 Global Transthyretin Stabilizer Sales Value by Application
4.2.1 Global Transthyretin Stabilizer Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Transthyretin Stabilizer Sales Value, by Application (2019-2030)
4.2.3 Global Transthyretin Stabilizer Sales Value, by Application (%) (2019-2030)
4.3 Global Transthyretin Stabilizer Sales Volume by Application
4.3.1 Global Transthyretin Stabilizer Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Transthyretin Stabilizer Sales Volume, by Application (2019-2030)
4.3.3 Global Transthyretin Stabilizer Sales Volume, by Application (%) (2019-2030)
4.4 Global Transthyretin Stabilizer Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Transthyretin Stabilizer Sales Value by Region
5.1.1 Global Transthyretin Stabilizer Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Transthyretin Stabilizer Sales Value by Region (2019-2024)
5.1.3 Global Transthyretin Stabilizer Sales Value by Region (2025-2030)
5.1.4 Global Transthyretin Stabilizer Sales Value by Region (%), (2019-2030)
5.2 Global Transthyretin Stabilizer Sales Volume by Region
5.2.1 Global Transthyretin Stabilizer Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Transthyretin Stabilizer Sales Volume by Region (2019-2024)
5.2.3 Global Transthyretin Stabilizer Sales Volume by Region (2025-2030)
5.2.4 Global Transthyretin Stabilizer Sales Volume by Region (%), (2019-2030)
5.3 Global Transthyretin Stabilizer Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Transthyretin Stabilizer Sales Value, 2019-2030
5.4.2 North America Transthyretin Stabilizer Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Transthyretin Stabilizer Sales Value, 2019-2030
5.5.2 Europe Transthyretin Stabilizer Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Transthyretin Stabilizer Sales Value, 2019-2030
5.6.2 Asia Pacific Transthyretin Stabilizer Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Transthyretin Stabilizer Sales Value, 2019-2030
5.7.2 South America Transthyretin Stabilizer Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Transthyretin Stabilizer Sales Value, 2019-2030
5.8.2 Middle East & Africa Transthyretin Stabilizer Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Transthyretin Stabilizer Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Transthyretin Stabilizer Sales Value
6.2.1 Key Countries/Regions Transthyretin Stabilizer Sales Value, 2019-2030
6.2.2 Key Countries/Regions Transthyretin Stabilizer Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Transthyretin Stabilizer Sales Value, 2019-2030
6.3.2 United States Transthyretin Stabilizer Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Transthyretin Stabilizer Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Transthyretin Stabilizer Sales Value, 2019-2030
6.4.2 Europe Transthyretin Stabilizer Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Transthyretin Stabilizer Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Transthyretin Stabilizer Sales Value, 2019-2030
6.5.2 China Transthyretin Stabilizer Sales Value by Type (%), 2023 VS 2030
6.5.3 China Transthyretin Stabilizer Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Transthyretin Stabilizer Sales Value, 2019-2030
6.6.2 Japan Transthyretin Stabilizer Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Transthyretin Stabilizer Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Transthyretin Stabilizer Sales Value, 2019-2030
6.7.2 South Korea Transthyretin Stabilizer Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Transthyretin Stabilizer Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Transthyretin Stabilizer Sales Value, 2019-2030
6.8.2 Southeast Asia Transthyretin Stabilizer Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Transthyretin Stabilizer Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Transthyretin Stabilizer Sales Value, 2019-2030
6.9.2 India Transthyretin Stabilizer Sales Value by Type (%), 2023 VS 2030
6.9.3 India Transthyretin Stabilizer Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Company Information
7.1.2 Pfizer Inc. Introduction and Business Overview
7.1.3 Pfizer Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Inc. Transthyretin Stabilizer Product Offerings
7.1.5 Pfizer Inc. Recent Development
7.2 Merck & Co.
7.2.1 Merck & Co. Company Information
7.2.2 Merck & Co. Introduction and Business Overview
7.2.3 Merck & Co. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Merck & Co. Transthyretin Stabilizer Product Offerings
7.2.5 Merck & Co. Recent Development
7.3 AstraZeneca Plc.
7.3.1 AstraZeneca Plc. Company Information
7.3.2 AstraZeneca Plc. Introduction and Business Overview
7.3.3 AstraZeneca Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.3.4 AstraZeneca Plc. Transthyretin Stabilizer Product Offerings
7.3.5 AstraZeneca Plc. Recent Development
7.4 GlaxoSmithKline Plc.
7.4.1 GlaxoSmithKline Plc. Company Information
7.4.2 GlaxoSmithKline Plc. Introduction and Business Overview
7.4.3 GlaxoSmithKline Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.4.4 GlaxoSmithKline Plc. Transthyretin Stabilizer Product Offerings
7.4.5 GlaxoSmithKline Plc. Recent Development
7.5 Corino Therapeutics Inc.
7.5.1 Corino Therapeutics Inc. Company Information
7.5.2 Corino Therapeutics Inc. Introduction and Business Overview
7.5.3 Corino Therapeutics Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Corino Therapeutics Inc. Transthyretin Stabilizer Product Offerings
7.5.5 Corino Therapeutics Inc. Recent Development
7.6 Alnylam Pharmaceuticals
7.6.1 Alnylam Pharmaceuticals Company Information
7.6.2 Alnylam Pharmaceuticals Introduction and Business Overview
7.6.3 Alnylam Pharmaceuticals Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Alnylam Pharmaceuticals Transthyretin Stabilizer Product Offerings
7.6.5 Alnylam Pharmaceuticals Recent Development
7.7 Bellus Health Inc.
7.7.1 Bellus Health Inc. Company Information
7.7.2 Bellus Health Inc. Introduction and Business Overview
7.7.3 Bellus Health Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Bellus Health Inc. Transthyretin Stabilizer Product Offerings
7.7.5 Bellus Health Inc. Recent Development
7.8 Ionis Pharmaceuticals, Inc.
7.8.1 Ionis Pharmaceuticals, Inc. Company Information
7.8.2 Ionis Pharmaceuticals, Inc. Introduction and Business Overview
7.8.3 Ionis Pharmaceuticals, Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Ionis Pharmaceuticals, Inc. Transthyretin Stabilizer Product Offerings
7.8.5 Ionis Pharmaceuticals, Inc. Recent Development
7.9 Proclara Bioscience
7.9.1 Proclara Bioscience Company Information
7.9.2 Proclara Bioscience Introduction and Business Overview
7.9.3 Proclara Bioscience Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Proclara Bioscience Transthyretin Stabilizer Product Offerings
7.9.5 Proclara Bioscience Recent Development
7.10 Arturus Therapeutics
7.10.1 Arturus Therapeutics Company Information
7.10.2 Arturus Therapeutics Introduction and Business Overview
7.10.3 Arturus Therapeutics Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Arturus Therapeutics Transthyretin Stabilizer Product Offerings
7.10.5 Arturus Therapeutics Recent Development
7.11 Prothena Corporation Plc.
7.11.1 Prothena Corporation Plc. Company Information
7.11.2 Prothena Corporation Plc. Introduction and Business Overview
7.11.3 Prothena Corporation Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Prothena Corporation Plc. Transthyretin Stabilizer Product Offerings
7.11.5 Prothena Corporation Plc. Recent Development
8 Industry Chain Analysis
8.1 Transthyretin Stabilizer Industrial Chain
8.2 Transthyretin Stabilizer Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Transthyretin Stabilizer Sales Model
8.5.2 Sales Channel
8.5.3 Transthyretin Stabilizer Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Pfizer Inc.
Merck & Co.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Corino Therapeutics Inc.
Alnylam Pharmaceuticals
Bellus Health Inc.
Ionis Pharmaceuticals, Inc.
Proclara Bioscience
Arturus Therapeutics
Prothena Corporation Plc.
听
听
*If Applicable.